• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Appoints Dorothy Gemmell as Chief Commercial Officer

    7/10/23 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    Gemmell to co-lead Pharma Manufacturer Solutions business, oversee GoodRx Health and Provider Mode

    GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company's Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies.

    Gemmell brings with her a strong track record leading high-growth teams and building trusted, market-leading healthcare companies that provide solutions to pharmaceutical companies, provider organizations and health plans. She has served as an advisor to GoodRx for two years, during which she focused on growth, go-to-market strategy and the development of GoodRx's healthcare provider offering, strengthening GoodRx's overall B2B value proposition to the pharmaceutical and medical device industry. With more than 30 years of industry experience, Gemmell will now work to expand the roster of brands that leverage GoodRx's leading awareness, access and adherence platform that is used by millions of consumers and has helped over 900,000 prescribers, and scale GoodRx's solutions for helping patients start and stay on their medications.

    "Dorothy is a successful, well-rounded healthcare executive with a terrific track record of building teams, delivering results for customers and creating revenue growth," said Scott Wagner, Interim CEO of GoodRx. "Dorothy knows GoodRx well and has a great combination of strategic insight and execution discipline. Everyone at GoodRx is thrilled that Dorothy is joining our team."

    In addition to working on Pharma Manufacturer Solutions, Gemmell will oversee the strategy and operations of GoodRx Health, the trusted and award-winning content arm of GoodRx, where she will continue building on its mission of creating impactful and unbiased health content for consumers. Gemmell will also manage the company's offerings for healthcare providers (HCPs), including the recently launched Provider Mode, which is a platform built to help HCPs find affordable solutions for the medications they prescribe.

    "I'm excited to join the GoodRx leadership team as we expand our opportunities for healthcare brands across our consumer and provider offerings," said Gemmell. "Grounded in our mission to make medications more affordable and accessible, I will be looking for new ways to help manufacturers surface their savings, adherence and patient support programs to providers and consumers in effective ways at the most meaningful points in the patient journey to improve patient outcomes."

    Gemmell previously served as Head of Commercial for digital pharmacy Capsule, Chief Commercial Officer for telebehavioral health company AbleTo, and held senior leadership roles at Havas Health, Practice Fusion and WebMD/Medscape. During her thirteen years at WebMD, she managed the sales teams and helped scale the company while building consumer and healthcare provider trust.

    About GoodRx

    GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $55 billion and are one of the most downloaded medical apps over the past decade.

    GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations, growth and financial results, our potential for growth, our relationship with industry participants and partners and other third parties, demand for our offerings, benefits to consumers from our offerings, and the benefits of new hires and anticipated contributions from Gemmell and Crittenden in their new roles. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and in our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230710669577/en/

    Get the next $GDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    More analyst ratings

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,719 shares, increasing direct ownership by 3% to 118,091 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/15/25 5:46:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 8% to 115,006 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/8/25 6:16:12 PM ET
      $GDRX
      EDP Services
      Technology
    • Director Idea Men, Llc converted options into 7,000,000 shares and returned $29,400,000 worth of shares to the company (7,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/21/25 4:23:24 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Financials

    Live finance-specific insights

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports Fourth Quarter and Full Year 2024 Results

      Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

      2/27/25 6:05:00 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/14/24 12:29:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/13/24 4:30:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/12/24 4:02:41 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    See more

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

      Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

      3/17/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

      Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

      2/5/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

      WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

      1/6/25 9:00:00 AM ET
      $GDRX
      $MAPS
      EDP Services
      Technology
      Computer Software: Prepackaged Software
    • GoodRx to Launch Direct Contracting for Independent Community Pharmacies

      GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide independent pharmacies with more direct control over pricing and favorable margins. GoodRx is committed to helping independent

      5/22/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      12/4/23 4:35:10 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/30/23 4:41:35 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/17/23 7:08:30 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/15/25 10:57:58 AM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/14/25 4:04:49 PM ET
      $GDRX
      EDP Services
      Technology
    • SEC Form 10-Q filed by GoodRx Holdings Inc.

      10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:50:11 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on GoodRx with a new price target

      Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

      12/4/24 7:38:07 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by Raymond James with a new price target

      Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

      8/9/24 7:30:17 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

      5/23/24 7:39:11 AM ET
      $GDRX
      EDP Services
      Technology